Drug intelligence / Profile preview

FL-802

Development stage: Preclinical
Lead developer: Full-Life Technologies
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
Administration: Intravenous

Overview

FL-802 is a preclinical-stage radionuclide drug conjugate (RDC) being developed by Full-Life Technologies. It targets B7-H3 (CD276), a transmembrane protein that is highly expressed in various solid tumors but has limited expression in normal tissues, making it an attractive target for cancer therapy. FL-802 utilizes Actinium-225 (Ac-225), an alpha-emitting radioisotope, to deliver targeted radiation to tumor cells, inducing DNA damage and cell death. The program is currently being evaluated for the treatment of several solid malignancies, including small cell lung cancer (SCLC), colorectal cancer (CRC), esophageal cancer, prostate cancer, and breast cancer.

Targets

B7-H3

Beyond the preview

Go deeper on FL-802.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FL-802.

Explore the full profile